Designation of Sodium Phenylbutrate (Pheburane) as an Orphan Drug - Orpharma Pty Ltd

Overview

The Therapeutic Goods Act 1989, enacted by the Commonwealth Parliament, establishes a framework for the regulation of therapeutic goods in Australia, ensuring their quality, safety, and efficacy. The Act aims to facilitate access to therapeutic goods that meet these standards while also addressing gaps in treatment options for rare and life-threatening conditions. In response to this, the Therapeutic Goods Administration designated sodium phenylbutrate (PHEBURANE) as an orphan drug on 13 August 2014 for the treatment of urea cycle disorders. This designation recognises the need for specialised treatments for rare diseases and supports the development and availability of such therapeutic goods by providing incentives to manufacturers. The policy objective is to improve health outcomes for patients with rare conditions by ensuring access to necessary medications that might otherwise not be commercially viable for broader populations.

Scope and Application

The Therapeutic Goods Act 1989, as amended, designates certain substances for specific medical uses, with the Therapeutic Goods Administration (TGA) having the authority to classify drugs based on their therapeutic value and necessity. In this instance, sodium phenylbutrate (PHEBURANE), a therapeutic product, has been designated as an orphan drug for the treatment of urea cycle disorders. This designation applies to the sponsor of the drug, Orpharma Pty Ltd, and is effective from 13 August 2014. The orphan drug designation is intended to encourage the development of treatments for rare diseases that affect a small number of people in the population, thereby ensuring that such treatments are available despite the limited market size. This Act applies across the Commonwealth of Australia, ensuring a uniform approach to the regulation and designation of therapeutic goods nationwide. The scope of the Act extends to entities involved in the research, production, and distribution of therapeutic goods, ensuring that they comply with the regulatory standards set forth by the TGA. The Act does not specify exclusions or exemptions but operates within the framework of the Therapeutic Goods Regulations 1990, which may further define the application and regulatory requirements through subordinate instruments.

Key Provisions

The Therapeutic Goods Act 1989 designates sodium phenylbutrate (PHEBURANE) as an orphan drug, specifically for the treatment of urea cycle disorders, as per the Therapeutic Goods Regulations 1990 (sections 16J and 16J(2)). This designation was made on 13 August 2014 by Dr Anthony Gill, the Delegate of the Secretary, and applies to the granules form of the drug. The sponsor of the drug is Orpharma Pty Ltd. This designation under the Act and Regulations recognises the therapeutic need and the rarity of the condition the drug is intended to treat. Under this designation, certain obligations and requirements are imposed on the parties involved. The sponsor, Orpharma Pty Ltd, must ensure that the drug meets the therapeutic needs for urea cycle disorders and comply with all relevant standards and guidelines as outlined in the Therapeutic Goods Act and Regulations. The Act requires that the drug be safe, of acceptable quality, and that its benefits outweigh any potential risks. Additionally, the sponsor must provide sufficient information to the Therapeutic Goods Administration (TGA) to support the orphan drug designation, including data on the rarity of the condition and the drug’s intended use. Failure to comply with the requirements of the Therapeutic Goods Act and Regulations may result in various penalties and consequences. The TGA has the authority to take enforcement actions against any party that breaches the regulations. Offences may include the supply of therapeutic goods that do not meet the required standards, which can lead to civil or criminal penalties. The maximum penalties for offences under the Act can include substantial fines, imprisonment, or both, depending on the nature and severity of the breach. Additionally, the TGA may impose administrative penalties, such as cancellation of the drug's registration or issuance of infringement notices, to enforce compliance with the Act and Regulations.